ÂÜÀòÂÒÂ×

Joe Anderson is a partner in the Sofinnova Crossover Strategy. He joined us in 2020 from Arix Bioscience plc, an LSE-listed venture capital firm where he was co-founder and CEO for 5 years.

Joe has extensive experience in the healthcare and life science industries, including 12 years as partner at Abingworth LLP, where he led venture-style investments in public companies and the formation of the firm’s public equities fund.

As an investor and active board member he has helped companies with financings, IPOs, and M&As, including Algeta (sold to Bayer for $2.9bn), Amarin (listed on the Nasdaq), Autolus (listed on the Nasdaq) and Cytos (merged with Kuros).

His early career was at the Wellcome Trust where he became head of the strategy group for 9 years.He then moved into equities research as a pharmaceuticals analyst at Dresdner Kleinwort Benson, and then fund management with the global healthcare & biotechnology fund at First State Investments, before moving into venture capital in 2004.

Joe holds a Ph.D. in Biochemistry.